On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

Sale to US private equity firm Clayton Dubilier & Rice comes as investors anticipate more and larger European PE buyouts ...

The French government has warned the United States investment company buying the consumer healthcare division of drugmaker ...

Ringworm (tinea), a fungal infection that affects the top layer of skin, hair, and nails, can be cured with over-the-counter ringworm medication or a prescription. Some people find that natural ...

Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...

French drugmaker Sanofi's confirmation that it will sell a controlling stake in its consumer health unit to a US investment ...

Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...

Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to ...

In the French government issued a stern warning to Clayton, Dubilier & Rice (CD&R), an American private equity firm, ...